Part B Drug Competitive Bidding Program Revival: Vendor Request Coming Soon
Executive Summary
Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.
You may also be interested in...
Part B Reform: HHS Proposal Is Intriguing – But Bigger Message Is Timing
“Immediate” actions on drug pricing reform aren’t necessarily happening soon, given that the competitive bidding proposal is just a request for information.
Medicare Value-Based Contracting, Vendor Price Negotiation To Be Tested In Part B Demo
CMS using authority from previously abandoned competitive acquisition program; vendors may get ability to use formularies and apply utilization management techniques like prior authorization and step therapy.
FDA Commissioner’s Rx For US Biosimilars Market: Reform Contracting Practices And Payment Models
In unveiling the agency’s Biosimilar Action Plan, FDA's Gottlieb continued his pattern of provocative remarks by criticizing brand company practices and payment models that impede biosimilar competition and could ultimately undermine innovation. He also called for more action by the Federal Trade Commission and downplayed the impact interchangeability could have on biosimilar uptake.